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Human genetic studies have recently suggested that
the postsynaptic activity-regulated cytoskeleton-
associated protein (Arc) complex is a convergence
signal for several genes implicated in schizophrenia.
However, the functional significance of Arc in schizo-
phrenia-related neurobehavioral phenotypes and
brain circuits is unclear. Here, we find that, consis-
tent with schizophrenia-related phenotypes, disrup-
tion of Arc in mice produces deficits in sensorimotor
gating, cognitive functions, social behaviors, and
amphetamine-induced psychomotor responses.
Furthermore, genetic disruption of Arc leads to con-
comitant hypoactive mesocortical and hyperactive
mesostriatal dopamine pathways. Application of a
D1 agonist to the prefrontal cortex or a D2 antagonist
in the ventral striatum rescues Arc-dependent cogni-
tive or psychomotor abnormalities, respectively. Our
findings demonstrate a role for Arc in the regulation
of dopaminergic neurotransmission and related be-
haviors. The results also provide initial biological
support implicating Arc in dopaminergic and behav-
ioral abnormalities related to schizophrenia.
INTRODUCTION
Schizophrenia is a devastating disorder strongly related to ge-
netic factors (Sullivan et al., 2003). This debilitating disorder is
defined by behavioral symptoms that encompass a large spec-
trum of abnormalities, including cognitive and sensorimotor
deficits, social withdrawal, and hallucinations. Although the
neurobiological mechanisms underlying these behavioral abnor-2116 Cell Reports 16, 2116–2128, August 23, 2016 ª 2016 The Autho
This is an open access article under the CC BY-NC-ND license (http://malities remain unclear, the pathophysiology of schizophrenia,
its treatments, and aspects of its associated behavioral deficits
have been consistently linked with a dysregulation of dopami-
nergic, glutamatergic, and GABAergic neural transmission,
especially in brain areas such as the prefrontal cortex (PFC)
and striatum (Howes and Kapur, 2009; Simpson et al., 2010;
Winterer and Weinberger, 2004).
Recent large-scalegenetic studies of schizophrenia havenoted
thatmany relevant variants involve genes encodingproteins inter-
acting with the activity-regulated cytoskeletal-associated (Arc)
postsynaptic signaling complexes (Fromer et al., 2014; Purcell
et al., 2014; Huentelman et al., 2015). Arc chromosomal micro-
deletion and intragenic SNPs have also been found in association
with neurodevelopmental disorders such as schizophrenia (Hu
et al., 2015;Huentelman et al., 2015). In addition, reduced expres-
sion of Arc mRNA has been detected in the PFC of individuals
with schizophrenia (Guillozet-Bongaarts et al., 2014). Despite
this consistent evidence pointing to convergence on Arc, the
neurobiological implication of Arc in schizophrenia-related be-
havioral phenotypes and brain systems remains unclear.
Arc is a neural activity-regulated immediate early gene that is
expressed selectively in Ca2+/calmodulin-dependent kinase II
alpha (CaMKIIa)-expressing neurons in the neocortex, hippo-
campus, and striatum (Miyashita et al., 2008; Vazdarjanova
et al., 2006). Extensive studies have shown that the Arc protein
is functionally involved in long-lasting forms of synaptic plasticity
(Plath et al., 2006; Shepherd et al., 2006; Rial Verde et al., 2006;
Waung et al., 2008; Park et al., 2008; Jakkamsetti et al., 2013). In
particular, Arc has been reported to regulate synaptic activities
and neuronal firing patterns through AMPA and NMDA-type
glutamate receptors (Chowdhury et al., 2006; Zhang et al.,
2015). Furthermore, genetic disruptions of the Arc gene have
been shown to impair experience-dependent cortical circuit
functions (McCurry et al., 2010; Wang et al., 2006) and consoli-
dation of memories (Plath et al., 2006; Ren et al., 2014; Caor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Impaired Sensorimotor Gating
and Social Abilities in Arc Knockout Mice
(A) Animal movements (a.u.) displayed by Arc+/+,
Arc+/, and Arc / littermates following the pre-
sentation of no stimulus or a 120 dB acoustic
stimulus (Startle).
(B) Percent PPI of the acoustic startle response
displayed by the same mice after the presentation
of 74, 78, 82, 86, and 90 dB prepulse stimuli.
n = 20–26/group. *p < 0.05, Arc/ versus Arc+/+.
(C and D) Time spent in each compartment of the
three-chambered arena during (C) the sociability
and (D) the social novelty tests displayed by Arc+/+,
Arc+/, and Arc / littermates. n = 9–17/group.
***p < 0.0005, **p < 0.005, and *p < 0.05 versus
the novel object or the novel mouse within the
same genotype. Values represent mean ± SEM
throughout all figures.et al., 2015). Although these results highlight a central role of Arc
in brain plasticity and in the regulation of two types of glutama-
tergic receptors (AMPA and NMDA) that have been implicated
in the pathophysiology of schizophrenia, whether genetic disrup-
tion of Arc will lead to schizophrenia-related behavioral and brain
system deficits is unknown.
Using genetically modified mice with targeted deletion of the
Arc gene, we aimed to investigate the effects of Arc genetic
disruptions on behavioral functions that have been studied in ro-
dents as relevant to schizophrenia. We did not attempt to find a
mousemodel of an entire psychiatric disorder but rather focused
on disease-related functional dimensions of behavior. Particu-
larly, because one of the long-standing pathophysiological
hypotheses of schizohprenia involves a dysregulated dopami-
nergic system (Weinstein et al., 2016), we investigated the
effects of Arc genetic disruption on different aspects of dopami-
nergic system functions. We found that Arc gene disruption
leads to behavioral abnormalities comprising a broad range
of cognitive, negative and positive schizophrenia-like symp-
toms. In addition, using a combination of ex vivo molecular as-
sessments, in vivo microdialysis, and electrical stimulation
coupled with in vivo two-photon imaging, we show that Arc
genetic disruption leads to divergent alterations between the
PFC and striatal dopaminergic system that capture aspects
of schizophrenia-related neuropathophysiology. Specifically,
reduced Arc gene expression resulted in a hypo-dopaminergic
response in the PFC and increased dopamine/D2 signaling in
the striatum. These data provide initial biological support that
abnormal Arc function may cause dysfunctions in the do-
paminergic system and behavioral abnormalities related to
schizophrenia.Cell RepRESULTS
Arc Genetic Disruption Impaired
Prepulse Inhibition Abilities, but
Not Startle Responses
Prepulse inhibition (PPI) is a sensorimotor
gating measure that is attenuated in
patients with schizophrenia (Swerdlowet al., 2006), is highly conserved across mammalian species, and
can be studied experimentally in rodents (Papaleo et al., 2012).
Reduction (+/) or absence (/) of Arc did not affect general
health or physical abilities (Table S1; Supplemental Results). Arc
genotype did not affect acoustic startle reactivity or basal activity
(F2,64 = 0.03, p = 0.97; Figure 1A). Instead, PPI showed a geno-
type effect (F2,64 = 4.46, p < 0.02; Figure 1B), with Arc
/ mice
displaying disrupted PPI (p = 0.008) and Arc+/mice a tendency
(p = 0.08) compared to Arc+/+ littermates. These results indicate
that genetic modifications reducing Arc decrease sensorimotor
gating abilities, consistent with PPI deficits in schizophrenia.
Arc Genetic Disruption Impaired Social Abilities
Disrupted social behaviors are characteristic features in schizo-
phrenia, embedded in so-called negative symptoms (Millan
et al., 2014). We thus assessed Arc+/+, Arc+/, and Arc / litter-
mates in a well-validated social approach task (Papaleo et al.,
2011).
Sociability, definedasspendingmore time in thechamberwitha
novel mouse than in the chamber with a novel object, was evident
in both Arc+/+ (F1,8 = 15.58, p < 0.005) and Arc
+/ (F1,16 = 22.31,
p<0.0005;Figure1C)mice. Incontrast,Arc/micepresentedso-
ciability deficits as they spent the same amount of time with the
novelmouse and the novel object (F1,5 = 0.63, p = 0.46; Figure 1C).
ThusArc deletion completely abolished social preference versus a
conspecific compared to an inanimate object.
Deficits in social novelty recognition were also detected in Arc
mutant mice. Arc+/+ mice spent more time in the chamber con-
taining the newly introduced mouse (novel mouse 2) than in
the chamber containing the now familiar mouse (F1,8 = 7.65,
p < 0.05; Figure 1D). In contrast, both Arc+/ and Arc / miceorts 16, 2116–2128, August 23, 2016 2117
Figure 2. Impaired Temporal Order and Spatial Object Recognition
Memory in Arc Knockout Mice
Discrimination ratio displayed by Arc+/+, Arc+/, and Arc/ littermates
(A) during the 5-min temporal order object recognition test (n = 18–20/group),
(B) during the 5-min spatial object recognition test (n = 17–22/group), and (C)
during the 5-min novel object recognition test (n = 6–12/group). *p < 0.01
versus Arc+/+ mice.spent the same amount of time between the newly introduced
and familiar mice (F1,16 = 0.67, p = 0.43 and F1,5 = 0.22, p =
0.66 for Arc+/ and Arc / mice, respectively; Figure 1D). For
both tests, entries into the left and right side chambers did not
differ within each genotype or across genotypes (Figure S1).
No innate side preference was observed across genotypes
before the start of the testing. These data indicate that genetic2118 Cell Reports 16, 2116–2128, August 23, 2016mutations reducing Arc disrupt social discrimination abilities,
consistent with similar deficits in schizophrenia.
Arc Genetic Disruption Produced Schizophrenia-
Relevant Cognitive Impairments
Cognitive deficits have been suggested as core symptoms of
schizophrenia. We tested Arc genetically modifiedmice in a tem-
poral order object recognition task that measures recency
discrimination, a cognitive ability disrupted in patients with
schizophrenia (Rizzo et al., 1996; Schwartz et al., 1991).
An Arc genotype effect was evident during the test phase
(F2,54 = 9.86; p < 0.0002; Figure 2A). In particular, the perfor-
mance of Arc+/ and Arc / mice was significantly worse than
that of Arc +/+ mice (p < 0.005). While Arc+/+ mice were spending
more time exploring the object presented least recently, Arc+/
andArc /mice failed to show any preference for the less recent
object. Thus, Arc genetic reduction impaired cognitive functions
dependent on the medial prefrontal cortex (mPFC), hippocam-
pus, and perirhinal cortex (PRH; Barker and Warburton, 2011).
To better dissect the neuroanatomical components of Arc-
dependent cognitive deficits, we tested two other cohorts of
naive mutants in a spatial object recognition task, exclusively
dependent on hippocampal functions, and in a novel object
recognition task that depends on the PRH, but not on the
mPFC or the hippocampus (Barker et al., 2007; Barker and War-
burton, 2011). In the spatial object recognition task, there was an
Arc effect (F2,54 = 10.66, p < 0.002; Figure 2B). In contrast to
Arc+/+ mice, Arc/ and Arc+/ mice were not able to recognize
which object was displaced (p < 0.003). These results indicate
that Arc is fundamental for spatial memory functions.
The novel object recognition task revealed no Arc effects
(F2,24 = 0.16; p = 0.85; Figure 2C). As well as Arc
+/+ mice,
Arc+/ and Arc /mice spent more time exploring the novel ob-
ject compared to the familiar one. This indicates unimpaired
novel-familiar object discrimination abilities and unaltered PRH
functioning. In all three experiments, Arc+/+, Arc+/, and
Arc / mice spent equal amount of time exploring the objects
in every phase of the task (Figure S2). Thus, Arc genetic reduc-
tion did not alter motivation, curiosity, motor, olfactory, tactile,
or visual functions that might affect object recognition.
Overall, these results indicate that the Arc-dependent cogni-
tive deficits might derive from a dysfunctional mPFC and/or hip-
pocampus, two brain regions implicated in the cognitive deficits
found in schizophrenia (Dreher et al., 2012; Rasetti et al., 2014).
Arc Genetic Disruption Produced Amphetamine
Supersensitivity
Amphetamine exacerbates psychotic experiences in patients
with schizophrenia and can be psychogenic in normal human
subjects (Laruelle et al., 1999). We thus tested Arc+/+, Arc+/,
and Arc / littermates in an open field arena in basal conditions
and following amphetamine injection.
A genotype3 time interaction effect was detected in the basal
locomotor activity during the first day (F22,572 = 1.98, p < 0.005).
All three genotypes decreased the distance traveled in the open
field arena over time. However, Arc/ mice were slightly
more active than Arc+/ and Arc+/+ mice during the first 5 min
(p < 0.05; Figure 3A).
Figure 3. Amphetamine Supersensitivity in Arc Knockout Mice
(A) Ambulatory distance displayed by Arc+/+, Arc+/, and Arc / littermates
during the first exposure to the empty open field arena (n = 14–24/group). *p <
0.05 versus Arc+/+ within the same time point.
(B) Ambulatory distance displayed by Arc+/+, Arc+/, and Arc / mice during
the 10 min before and 60 min after the amphetamine injection (1.5 mg/kg, i.p.)
(n = 13–20/group).
*p < 0.01 and **p < 0.001 versus Arc+/+ and Arc+/.Two days later, a genotype effect was present again during the
first 10 min in the open field (F2,42 = 4.97, p% 0.01), with Arc
/
mice being more active than Arc+/+ and Arc+/ mice (p < 0.008;
Figure 3B). Afterward, mice were injected with amphetamine
(1.5 mg/kg), revealing a genotype 3 time interaction effect
(F22,462 = 1.92, p < 0.008). Locomotor activity responses to
amphetamine were higher in Arc/ mice than in Arc+/ and
Arc+/+ mice (p < 0.005; Figure 3B). Thus, genetic mutations dis-
rupting Arc produced a hyperactive phenotype and amphet-
amine supersensitivity consistent with rodents’ correlates of
schizophrenia-like symptoms. Importantly, these results may
suggest a previously unexpected effect of Arc in the modulation
of the dopaminergic system.
Arc Genetic Disruption Decreased Dopamine Turnover
in the PFC and Increased Post-synaptic D2 Signaling in
the Striatum
To investigate howArcgeneticmutationsmight affect thedopami-
nergicsystem,wefirstanalyzedArcmutants fordopaminecontent
in PFC and striatum, two major areas involved in the dopaminehypothesis of schizophrenia (Koch et al., 2014; Simpson et al.,
2010; Weinstein et al., 2016; Winterer and Weinberger, 2004). In
the PFC, an Arc effect was present on dopamine tissue content
(F2,71 = 6.72, p = 0.002; Figure 4A), but not on noradrenaline
(Figure S3). Arc/ mice had increased dopamine levels (p =
0.003) and a decrease in both the HVA:dopamine and
DOPAC:dopamine ratios (p<0.05;Figures4Band4C), suggesting
a decreased dopamine turnover. In agreement, measurements of
tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine
synthesis, revealed that Arc knockout mice had reduced
pTH(Ser40) levels (F2,15 = 9.58, p < 0.003; Figure 4D), a marker of
TH enzymatic activity (Anzalone et al., 2012), and normal TH total
protein levels (p = 0.7; Figure 4E). In contrast, in the striatum there
was no Arc-dependent effect on the dopamine content (F2,47 =
0.46, p = 0.63; Figure S3) or onHVA andDOPAC ratios (FigureS3).
These results indicate that Arc genetic disruption affects the
maintenance of dopaminergic transmission in the PFC.
Alterations of the dopamine system in the PFC can change D2
receptor transmission in the striatum (Clarke et al., 2014; Pycock
et al., 1980), and dopamine/D2 pathways in the PFC-striatal loop
have been implicated in the manifestations of schizophrenia
(Simpson et al., 2010; Winterer and Weinberger, 2004). Thus,
we next analyzed total and surface protein levels of the D2 re-
ceptors in Arc mutants. Genetic reduction of Arc (both +/
and /) increased surface D2 in the striatum (F2,6 = 228.41,
p < 0.0001, Figure 4F), but not in the PFC (F2,6 = 1.98, p =
0.22; Figure S4). In contrast, no Arc effect was evident in the total
levels of D2 in the striatum (F2,6 = 0.16, p = 0.85; Figure 4G) and
PFC (F2,6 = 0.59, p = 0.58; Figure S4). Several studies indicate
that increased D2 transmission in the striatum is an important
component in the pathophysiology of schizophrenia (Abi-Darg-
ham et al., 2000; Laruelle, 1998; Simpson et al., 2010; Winterer
and Weinberger, 2004; Kellendonk et al., 2006). In particular,
D2 density and surface availability is increased in drug-naive
or drug-free patients with schizophrenia (Abi-Dargham et al.,
2000; Laruelle, 1998).
To further examine striatal D2 signaling in Arc knockout mice,
we analyzed total and phosphorylated levels of different dopa-
mine/D2-related intracellular regulatory proteins in baseline con-
ditions and following the amphetamine challenge used for
behavioral experiments. The Ser40 pTH levels have been directly
correlated with the activity of pre-synaptic D2 (Anzalone et al.,
2012). Consistent with this, we found that amphetamine reduced
striatal pTH levels (F1,30 = 5.83, p < 0.02), but in an Arc-indepen-
dent manner (F2,30 = 0.31, p = 0.74; Figure 4I). The total levels of
TH were unassociated with Arc (F2,34 = 0.74, p = 0.49), as well as
with amphetamine treatment (F1,34 = 0.13, p = 0.72, Figure 4H).
Thus, our data suggest that Arc might not alter presynaptic D2
pathways in the striatum.
Reduced expression of Akt kinase has been reported in pa-
tients with schizophrenia (Emamian et al., 2004; Zhao et al.,
2006). We found a similar reduction of total Akt under basal con-
dition in both Arc+/ and Arc /mice (F2,32 = 8.97 p < 0.001; Fig-
ure 4J). The thr308 pAkt levels have been directly correlated with
the activity of postsynaptic D2 (Beaulieu et al., 2007). We found
that at the basal level, Arc/mice had reduced pAkt compared
to Arc+/+ mice (F2,29 = 4.77, p < 0.01; Figure 4K). Following
amphetamine treatment, Arc knockout mice did not show furtherCell Reports 16, 2116–2128, August 23, 2016 2119
Figure 4. PFC Decreased Dopamine Turnover and Striatal Increased Post-synaptic D2 Signaling in Arc Knockout Mice
(A–E) Total dopamine (DA) content expressed as nanograms per milligram of tissue (A), HVA:DA (B) and DOPAC:DA (C) metabolite ratios, levels of TH phos-
phorylated at the Ser40 site (pTH Ser40) (D), and TH in dissected PFC (E) of Arc+/+, Arc+/, and Arc / littermates (n = 14–20/group for HPLC, n = 5–7/group for
western blots). *p < 0.05 versus Arc+/+ mice.
(F–K) Densitometric analyses of D2 receptors (F and G) and relative levels of total TH (H), pTH (Ser40) (I), total Akt (J), and pAKT (Thr-308) (K) in dissected striatum
of Arc+/+, Arc +/, and Arc/ littermates. For the D2 analysis, striatal samples were loaded 1:20 compared to PFC samples, and for each brain area, the input was
1:10 compared to the pull down. Samples without Streptavidin beads and Synaptophysyn proteins were used as a pulldown control. Data are normalized to
transferrin receptor proteins. For total TH and Akt levels, actin was used as loading controls, while for measurement of phospho-protein levels, total protein were
used as a loading control. *p < 0.05 and ***p < 0.0005 versus Arc+/+. #p < 0.05 versus Arc+/+ within the same treatment, $p < 0.05 versus Arc+/+. Representative
western blots are shown in Figure S7.reduction in pAkt, in contrast to wild-type mice. Taken together,
the D2 expression and Akt data (Figures 4F–4K) suggest that Arc
disruption increased postsynaptic dopamine/D2 signaling in the2120 Cell Reports 16, 2116–2128, August 23, 2016striatum. Notably, mice with selective overexpression of post-
synaptic D2 in the striatum showmolecular and behavioral alter-
ations (Kellendonk et al., 2006) overlapping with Arc knockout
Figure 5. Opposite Regulation of Amphet-
amine-Evoked Dopamine Release in the
mPFC and Nucleus Accumbens Shell in
Freely Moving Arc Knockout Mice
(A, C, and E) Coronal sections showing the
placements in mPFC (A), ventral striatum nucleus
accumbens (NAc) shell portion (C), and dorsal
striatum (E) of the in vivo microdialysis probes.
(B, D, and F) Effect of amphetamine (1.5mg/kg i.p.)
on the dopamine (DA) dialysate levels in mPFC (B),
nucleus accumbens shell (D), and dorsal striatum
(F) in freely moving Arc+/+, Arc+/, and Arc /
littermates.
Data are expressed as the percentage of change in
dopamine extracellular levels from the basal
values. Inset quadrants show basal values of
extracellular dopamine expressed as fmol/20 ml
sample. n = 6–8/group. ***p < 0.0005 and **p <
0.005 versus Arc+/ and Arc / within the same
time point.mice, further supporting Arc as a converging point of schizo-
phrenia genetics.
Arc Genetic Disruption Dampened Amphetamine-
Induced Dopamine Release in the mPFC but Intensified
It in the Nucleus Accumbens Shell
To directly andmore precisely characterize the active processes
of dopamine release, we measured its dynamics in the extrasy-
naptic space by in vivo microdialysis in freely moving Arc+/+,
Arc+/, and Arc / littermates.
Notably, the same amphetamine challenge to which Arc
knockout mice were supersensitive revealed a genotype effectCell Repon dopamine release in the mPFC
(F2,20 = 6.1, p < 0.009; Figures 5A and
5B), in the ventral striatum at the level of
nucleus accumbens shell (F2,11 = 4.31,
p < 0.05; Figures 5C and 5D), but not in
the dorsal striatum (F2,17 = 0.87, p =
0.44; Figures 5E and 5F). In particular,
compared to wild-type mice, amphet-
amine-dependent dopamine release in
Arc knockout mice was reduced in the
mPFC (p < 0.02; Figure 5B) but increased
in the nucleus accumbens shell (p < 0.05;
Figure 5D). We also replicated in these
same mice the Arc-dependent locomotor
supersensitivity to amphetamine (Fig-
ure S5). Consistently, previous studies
indicated that pharmacological inhibition
of PFC dopaminergic input leads to su-
persensitivity in amphetamine-induced
locomotion (Tzschentke, 2001), and
amphetamine-induced locomotion is pre-
ferentially related to an increase in dopa-
mine neurotransmission in the nucleus
accumbens shell more than to dorsal
striatum (Ikemoto, 2002; Heidbreder andFeldon, 1998). Together with the ex vivo measurements (Fig-
ure 4), these findings indicate that Arc genetic disruption results
in a hypoactive PFC and a hyperactive striatal dopaminergic sys-
tem. Importantly, these data parallel similar findings in patients
with schizophrenia (Slifstein et al., 2015; Howes and Kapur,
2009).
Arc Genetic Disruption Reduced VTA-Induced Cortical
Activity in the PFC
We next examined whether Arc PFC deficit may be associated
with changes in frontal cortical activity. Electrophysiological
studies have shown that dopaminergic input plays an importantorts 16, 2116–2128, August 23, 2016 2121
Figure 6. VTA-Induced PFC Activation Is
Reduced in Arc Knockout Mice, and This
Reduction Is Recovered by Pharmacolog-
ical Activation of D1 Receptors
(A) Diagram showing the experimental setup for
imaging VTA-stimulation evoked frontal cortical
response (left). An AAV virus encoding a synapsin-
promoter-driven calcium reporter GCaMP6 was
locally injected into the PFC. GCaMP6 fluores-
cence was imaged in the superficial layers of the
PFC by two-photon microscopy (right). Scale
bar, 15 mm.
(B) Time courses of cortical calcium signals in
response to VTA stimulation in Arc+/+ and Arc /
mice. One, five, or ten pulses of electrical stimuli
(50 Hz) were delivered at 20 s after the start of
imaging. The cortical calcium activity at each
time point is represented by the change in image
fluorescence relative to the baseline image
fluorescence (DF/F). n = 6/group, **p < 0.001
versus Arc+/+.
(C) Time courses of VTA-stimulation evoked
cortical responses in Arc/ mice before and
after saline or D1 agonist SKF38393 injection
(10 mg/kg, i.p.). Ten pulses of electrical stimuli
(50 Hz) were delivered at 20 s after the start of
imaging in each session. The frontal cortical acti-
vation was significantly increased after SKF38393
injection (*p < 0.02). n = 6/group.
(D) Total amount of calcium activity in the PFC
following ten-pulse (50-Hz) VTA stimulation (sum
of 20–35 s) showing significant reduction in Arc/
compared to Arc+/+ mice (**p < 0.006) and signifi-
cant increase in Arc/ mice after SKF compared
to before SKF (*p < 0.02). No significant difference
between Arc+/+ and Skf-injected Arc/ animals
(p = 0.40). n = 6/group.role in regulating the activity of frontal cortical neurons (Robbins
and Arnsten, 2009). For example, burst electrical stimulation of
dopamine neurons in midbrain ventral tegmental area (VTA)
evokes sustained neural activity in the frontal cortex (Lavin
et al., 2005; Mastwal et al., 2014).
To efficiently sample the activity of neurons in the PFC and
compare cortical activity between Arc wild-type and knockout
mice, we adopted an in vivo optical imaging approach. We ex-
pressed the genetically encoded calcium sensor GCaMP6 in
frontal cortical neurons through a locally injected adeno-associ-
ated virus (AAV) vector, and applied in vivo two-photon micro-
scopy to image cortical calcium responses to VTA electrical
stimulation (Figure 6A). While calcium activity cannot be equated
with dopamine activation, we conducted experiments to test
whether reduced dopamine release in the PFC of Arc knockout
mice would lead to reduction in mesofrontal circuit activation.2122 Cell Reports 16, 2116–2128, August 23, 2016In wild-type mice, we observed a
robust activation of the PFC, as repre-
sented by the increase of calcium activity,
in response to burst stimulation of VTA
(Figure 6B). However, in Arc knockout an-
imals, the activation of PFC in response to
VTA stimulation was reduced comparedto Arc+/+ animals (Figure 6B). This difference in activation be-
comes more prominent with increasing strength of VTA stimula-
tion (F1,10 = 20.94, p = 0.001). Thus, our results show that the
reduction of evoked cortical dopamine levels in Arc knockout
mice is associated with reduced cortical response to VTA
stimulation.
We next tested whether the impaired prefrontal response to
VTA stimulation in Arc knock out mice could be rescued by phar-
macologically enhancing dopaminergic signaling. Dopamine D1
receptors have been suggested to mediate the sustained neural
activity of the frontal cortex in response to VTA activation (Lewis
and O’Donnell, 2000). We confirmed that VTA evoked calcium
responses in the PFC of wild-type mice were reduced by dopa-
mine/D1 antagonist (Figure S6). Moreover, we administered
D1 agonist SKF38393 (10 mg/kg, intraperitoneally [i.p.]) to Arc
knockout mice and found that VTA-evoked frontal cortical
Figure 7. Pharmacological D1 Stimulation
inmPFCandD2 Inhibition in theNucleus Ac-
cumbens Shell Rescued Arc-Dependent
Cognitive and Dopamine/Locomotor Defi-
cits, Respectively
(A) Discrimination ratio displayed by Arc+/+, Arc+/,
and Ar / littermates treated 15 min before the
retrieval phase of the temporal order object
recognition task with vehicle or the dopamine D1
agonist SKF38393 (0.06 mg in 0.3ml), bilaterally
microinjected in the mPFC (n = 5–15/group).
*Groups showing no discrimination.
(B) Coronal sections showing the injection sites in
mPFC for Arc+/+ (circles), Arc+/ (triangles), and
Arc/ (squares).
(C) Dopamine extracellular levels measured by
in vivo microdialysis in the nucleus accumbens
shell of freely moving Arc+/+, Arc+/, and Arc /
littermates in basal conditions, following the infu-
sion of the D2-like antagonist eticlopride (1 mM)
with reverse dialysis (30 min alone, and 2 hr after
the i.p. injection of amphetamine 1.5 mg/kg) and
during the 1-hr washout period. Data are ex-
pressed as the percentage of change in dopamine
extracellular levels from the basal values. Basal
values of extracellular dopamine (expressed as
fmol/20-ml sample) are shown in the inset quad-
rants. n = 5–6/group.
(D) Ambulatory distance displayed by these same
Arc+/+, Arc+/, and Arc/ mice while going
through the different phases of the in vivo micro-
dialysis experiment.
(E and F) Differences in dopamine levels (E),
ambulatory activity (in beam crossing) (F), and
basal dopamine levels (inset) between the day of
eticlopride infusion and the day without eticlopride
in Arc+/+, Arc+/, and Arc /mice. **p < 0.005 and
*p < 0.05 versus Arc+/+.activation was significantly increased in contrast to saline control
(p < 0.027, F1,5 = 9.63; Figure 6C). The total amount of calcium
activity in the frontal cortex following ten-pulse (50 Hz) VTA
stimulation was not different between Arc+/+ and SKF38393-in-
jected Arc/ animals (p = 0.397; Figure 6D), indicating that the
deficit in Arc/mice is rescued by D1 agonist treatment. Taken
together, these data support a deficiency of dopaminergic
modulation in the PFC of Arc knockout mice and suggest that
enhancing D1 signaling can rescue this circuit deficit.
D1 Stimulation in mPFC and D2 Inhibition in the Ventral
Striatum Reverses Cognitive and Psychomotor Deficits,
Respectively, in Arc Knockout Mice
The suggested dopaminergic imbalance in schizophrenia seems
to involve a hypostimulation of D1 receptors in the PFC, as a
possible mediator of negative symptoms and cognitive impair-
ment, and a hyperstimulation of D2 receptors in striatal regions,
as a possible mediator of positive symptoms (Slifstein et al.,
2015; Tzschentke, 2001; Winterer and Weinberger, 2004).
Thus, guided by our first findings (Figures 3, 4, 5, and 6), we
directly tested this hypothesis in Arc knockout mice.To rescue putatively PFC-dependent cognitive impairment in
Arc mutant mice, we applied dopamine D1 agonist SKF38393
in the mPFC during the temporal order object recognition
task. A genotype-by-treatment interaction effect was evident
(F2,47 = 3.87, p = 0.02). In agreement with the in vivo two-
photon optical imaging data (Figure 6), pre-test microinjection
of the dopamine D1 agonist in the mPFC rescued the cognitive
deficits found in Arc+/ mice (t = 5.36; df = 6; p = 0.002; Fig-
ure 7A) and partially in Arc/ mice (t = 2.57; df = 4; p =
0.08; Figure 7A). In contrast, SKF38393 in the mPFC disrupted
temporal order object recognition in wild-type mice (t = 1.08;
df = 6; p = 0.32; Figure 7A). In mPFC vehicle-treated mice,
we replicated the inabilities of Arc+/ mice (t = 0.35; df = 14;
p = 0.73) and Arc/ (t = 1.14; df = 5; p = 0.31) to distinguish
between the object presented less recently and the one pre-
sented more recently (Figure 7A). These data are consistent
with the inverted U-shaped relationship between cortical
dopamine and cognitive performance (Papaleo et al., 2014;
Vijayraghavan et al., 2007) and suggest that Arc genetic disrup-
tion generated dopamine/D1-mediated PFC deficiency and
related cognitive deficits.Cell Reports 16, 2116–2128, August 23, 2016 2123
To rescue the psychomotor hyperactivity in Arc mutant mice,
we applied D2-like antagonist eticlopride in the nucleus accum-
bens shell. The local infusion of eticlopride abolished the
amphetamine-supersensitivity of Arc knockout mice, in terms
of both dopamine release (F2,55 = 1.70, p = 0.23, Figure 7C)
and locomotor responses (F2,55 = 1.52, p = 0.26, Figure 7D).
These data demonstrate that Arc knockout mice are more
sensitive to a D2 antagonist. Compared to the phenotypes of
these mice in the absence of eticlopride treatment, the D2
antagonism did not cause any significant change in +/+ mice,
but consistently reduced dopamine release (F2,55 = 8.17, p =
0.007; Figure 7E) and corresponding locomotor activation
(F2,55 = 5.56, p = 0.02; Figure 7F) in Arc
+/ and Arc /mice. Pre-
vious studies have indicated that elevated dopamine transmis-
sion in nucleus accumbens leads to hyperlocomotion (Ikemoto,
2002) and D2 antagonism in nucleus accumbens reduces
psychostimulant-induced locomotion in a dose-dependent
manner (Baker et al., 1996; Chausmer and Ettenberg, 1999;
van den Boss et al., 1988). The stronger effect of eticlopride on
amphetamine-induced locomotor activity in Arc mutant mice
compared to Arc+/+ mice is consistent with the elevated surface
expression of D2 receptors in Arcmutant mice (Figure 4F). Taken
together, these data suggest that the supersensitivity to amphet-
amine found in Arc knockout mice is mediated by altered D2
signaling in the striatum.
DISCUSSION
The data reported here show that genetic mutations resulting in
loss or reduction in Arc function cause behavioral features span-
ningmultiple domains of rodent correlates of cognitive, negative,
and positive schizophrenia-like symptoms. Furthermore, our
data implicate a previously unexplored role of Arc as amodulator
of the brain dopaminergic system. The observed changes were
consistent with a notion of schizophrenia pathophysiology that
includes a hypodopamine/D1 functioning in the PFC but a hyper-
dopamine/D2 system in striatal regions. These findings provide
initial biological evidence that genetic variations resulting in
impaired Arc function contribute to pathophysiologic correlates
of schizophrenia.
Arc knockout mice recapitulated many behavioral abnormal-
ities considered rodent correlates of schizophrenia-like symp-
toms. In particular, Arc knockout deficits in PPI are analogous
to PPI deficits found in patients with schizophrenia (Swerdlow
et al., 2008). Similarly, the deficits in Arc knockout mice in socia-
bility and social cognition are potentially mouse correlates of low
social reciprocity and deficits in social cognition found in schizo-
phrenia (Millan et al., 2014). Furthermore, Arc knockouts impair-
ments in the temporal order and spatial object recognition tasks,
with a preserved ability to recall and recognize objects in the
novel object recognition task, is reminiscent to cognitive deficits
found in schizophrenia. Indeed, patients with schizophrenia
show analogous impairments in temporal and spatial memory
tasks, while they are able to recall and recognize target items
(Dreher et al., 2001; Schwartz et al., 1991; Rizzo et al., 1996; Fol-
ley et al., 2010). Finally, Arc knockout mice’s slight hyperactivity
in a novel environment and amphetamine supersensitivity might
parallel psychotic agitation and amphetamine’s ability to be psy-2124 Cell Reports 16, 2116–2128, August 23, 2016chogenic in healthy subjects and to exacerbates psychotic ex-
periences in patients with schizophrenia (van den Buuse, 2010).
Earlier studies of Arc knockout mice have emphasized the def-
icits in long-term memory tasks such as the Morris water maze,
auditory fear conditioning, and taste aversion, whereas the gen-
eral performance and short-term memory of the knockout mice
in these tasks were mostly normal (Plath et al., 2006). In this
study, all the behavioral tasks were performed without prior
training and do not require formation of long-term episodicmem-
ory. The deficits in these tasks therefore may reflect a pre-exist-
ing deficit in the steady-state function of the underlying brain
circuits rather than the consolidation of new memories. Notably,
the behavioral tasks reported in earlier studies mainly rely on
the visual cortex, auditory cortex, taste cortex, hippocampus,
or amygdala (Plath et al., 2006). By contrast, the tasks used in
the current study involve PFC and also the dopaminergic system
(Barker et al., 2007; Hanks et al., 2013; Lacroix et al., 2000;
Tzschentke, 2001). These findings raise the possibility that the
different susceptibility of behavioral tasks to Arc genetic disrup-
tion may reflect differences in the underlying brain circuits.
Furthermore, in the cortex and hippocampus, Arc is only ex-
pressed in the CamKII-positive excitatory neurons (Ren et al.,
2014; Vazdarjanova et al., 2006). Thus, Arc genetic disruption
will not directly affect interneuron function in a cell-autonomous
manner. However, as Arc genetic disruption leads to changes of
both glutamate receptors in excitatory neurons and dopamine
release, cortical inhibitory neuron activities will be affected
through network interactions with dopamine and glutamatergic
neurons. Some of the behaviors we assessedmay indeed reflect
this network level imbalance, as what has been proposed for the
pathophysiology of schizophrenia.
More surprisingly, following Arc disruption, we identified con-
trastingdeficits in themesocorticalandmesostriataldopaminergic
pathways. The Arc-dependent effects found in the PFC and in the
ventral striatum, but not in the dorsal striatum, might be related to
the fact that the source of dopamine in both the PFC and nucleus
accumbens is the VTA, while in the dorsal striatum, it is the
substantia nigra (Beckstead et al., 1979). The opposite effects of
Arc genetics in amphetamine-induced dopamine release in PFC
versus nucleus accumbens might originate from a circuit mecha-
nism. Previous pharmacological studies have suggested that
dopamine transmission in the PFC and nucleus accumbens are
inversely coupled (Scornaiencki et al., 2009; Simpson et al.,
2010; Tzschentke, 2001) and direct anatomical connections with
opposite feedbacks exist among the PFC, VTA, and nucleus
accumbens to mediate these effects (Carr and Sesack, 2000;
Ferenczi et al., 2016). Remarkably, the Arc-dependent dopami-
nergic alterations resemble abnormalities considered key features
in patients with schizophrenia (i.e., hypoactive D1 mesocortical
and hyperactive D2 mesostriatal pathways) (Simpson et al.,
2010; Slifstein et al., 2015; Winterer and Weinberger, 2004). Our
findings suggest that Arc function is important for establishing
theproperactivitybalancebetweenmesocorticalandmesostriatal
dopaminergic circuits. Moreover, our studies further suggest that
these circuit deficits can arise together from the same genetic
background, which has been difficult to determine in humans
due to different dopamine molecular imaging methods in striatal
and cortical regions and genetic diversity (Weinstein et al., 2016).
Previous studies have reported that PFC dopaminergic inputs
show protracted postnatal maturation through adolescence and
are susceptible to activity-dependent modification during this
period (Kalsbeek et al., 1988; Lewis and O’Donnell, 2000;
Mastwal et al., 2014). Recurrent network activity in frontal-striatal
loops can also affect striatal circuit maturation (Kozorovitskiy
et al., 2012). As a neural activity-induced plasticity-related pro-
tein abundantly expressed in cortical excitatory and striatal
GABAergic projection neurons (but not detected in midbrain
dopamine neurons) (Shepherd and Bear, 2011), Arc may regu-
late activity-dependent maturation of the VTA-PFC-striatal cir-
cuits during postnatal development. Considering the well-known
role of Arc in modulating glutamate receptors (Jakkamsetti et al.,
2013; Ren et al., 2014; Shepherd and Bear, 2011), our findings
raise the possibility that Arc-dependent changes in glutamater-
gic signaling might be the effector of the dopamine system
changes. Since alterations in mesocortical and mesostriatal
dopaminergic pathways are often inversely coupled to each
other (Clarke et al., 2014; Simpson et al., 2010; Tzschentke,
2001; Saunders et al., 1998), future studies are needed to differ-
entiate the cell-autonomous and network effects of Arc genetic
disruption.
In conclusion, Arc knockout mice recapitulate important fea-
tures of rodent correlates of schizophrenia-related functional di-
mensions. Moreover, we describe a previously unexplored role
of Arc in the modulation of dopaminergic neurotransmission,
again consistent with schizophrenia-relevant endophenotypes.
Together with the already well-known role of Arc in the modula-
tion of the glutamatergic signaling (Ren et al., 2014; Jakkamsetti
et al., 2013; Shepherd and Bear, 2011), the present data strongly
implicate Arc as a key regulator of biological features associated
with schizophrenia that involve PFC-striatal dopaminergic
circuitry. Indeed, Arc may provide not only a converging point
for genes encoding for glutamatergic post-synaptic proteins
(Fromer et al., 2014) but also a crucial link between the dopami-
nergic and glutamatergic fronto-striatal systems.
EXPERIMENTAL PROCEDURES
Subjects
All procedures were approved by the Italian Ministry of Health (permit n. 230/
2009-B) and local animal use committee and were in accordance with the
Guide for the Care and Use of Laboratory Animals of the NIH and the European
Community directives. Arc knockout mice (Wang et al., 2006) of both sexes
(3–7 months old) were used. Because no sex-dependent differences were
found in anyparametermeasured,male and femalemicewerepooled together.
Arc null mutant (/) mice and their heterozygous (+/) and wild-type (+/+) lit-
termates were bred in-house by +/mating. Mice were housed two to four per
cage, in a climate-controlled animal facility (21 ± 2C), and maintained on a
12-hr light/dark cycle (7 a.m. to 7p.m.)with ad libitumaccess to food andwater.
Testing was conducted during the light phase. Different cohorts of mice were
used for each task. Experimenters were blind to the genotype during testing.
Behavioral Experiments
Startle, PPI, and general health parameters were measured as previously
described (Papaleo et al., 2008, 2012).
Locomotor activity, temporal order, spatial and novel object recognition
tasks were performed as previously described (Huang et al., 2014; Papaleo
et al., 2008; Barker et al., 2007).
Sociability and preference for social novelty task as previously described
(Papaleo et al., 2011).TOR with Skf Treatment
Mice were bilaterally implanted with 7-mm-long stainless steel guide cannulae
(Unimed) under an isoflurane/oxygenmixture anesthesia. ThemPFC stereotax
coordinates used were antero posterior (AP) +1.95 mm, lateral (L) ±0.5 mm,
and dorso ventral (DV) 1.5 mm, relative to the bregma (Franklin and Paxinos,
1997). Guide cannulae were secured in place with dental cement. Mice were
then allowed to recover for 7 days after surgery. The Skf38393 D1 agonist
(Sigma-Aldrich) was dissolved in 0.9% saline solution and then injected in a
dose of 0.06 mg/0.3 ml/side. An injection needle was inserted into the guide
cannula protruding 1 mm below (final DV, 2.5 mm), which was connected
by plastic tubing to a 10-ml Hamilton syringe; the process took 1 min, with
an additional 1 min to allow diffusion. The drug injection was performed
15 min before the temporal order object recognition task (TOR) testing phase.
At the completion of the experiments, mice were sacrificed, and the brains
were removed and fixed in a 4% paraformaldehyde solution. Cannula place-
ments were determined by examining serial 80-mm coronal sections stained
with cresyl violet.
HPLC
For dopamine determination by HPLC, PFC and striatum were rapidly
dissected from naive Arc/, Arc+/, and Arc+/+ littermates, immediately frozen
in dry ice, and then stored at 80C. Samples were then lysed in 0.1 M
perchloric acid, then sonicated and spun in a microcentrifuge at 10,000 3 g
for 10 min. The supernatant was transferred in ultra-free microcentrifuge tubes
(Millipore, catalog UFC30GV0S) and spun for 2 min. Samples (11 ml) were in-
jected into the HPLC and measurements of dopamine and metabolites were
made with an electrochemical detection system (ALEXYS LC-EC; Antec
Leyden BV) equipped with a reverse-phase column (3-mm particles,
ALB-215 C18, 1 3 150 mm; Antec Leyden BV) at a flow rate of 200 ml/min
and electrochemically detected by a 0.7-mm glass carbon electrode (VT-03;
Antec Leyden BV). The mobile phase contained 50 mM H3PO4, 50 mM citric
acid, 8 mM KCl, 0.1 mM EDTA, 400 mg/l octanesulfonic acid sodium salt,
and 3% (v/v) methanol (pH 75).
In Vivo Microdialysis
Vertical concentric dialysis probes, with a dialyzing portion of 2 mm for dorsal
striatum andmPFC and 1mm for nucleus accumbens shell, were prepared us-
ing AN69 fibers (Hospal Dasco), as previously described (De Luca et al., 2014).
More details can be found in Supplemental Experimental Procedures.
Electrical Stimulation Coupled with In Vivo Two-Photon Imaging
Viral Injection
Using a glass micropipette connected to a 10-ml Hamilton syringe and a
syringe pump, AAV1.Syn.Flex.GCaMP6s.WPRE.SV40 (1 ml) was injected into
a single site in the PFC (from bregma: AP +2.0, medio lateral [ML] +0.5, and
DV 0.3 mm) of Arc+/+ and Arc / littermates. Animals were allowed to
recover for 1–2 weeks.
Electrode Implantation and Cranial Window
A bipolar stimulation electrode was lowered into the VTA (from bregma: AP
3.2 mm, ML 0.5 mm, and DV 4.5 mm) and glued in place in animals anesthe-
tized with isoflurane (1.5%). A cranial window was opened above the
AAV-GCaMP6 injected region in the frontal cortex (from bregma: AP 1.0–
3.0 mm, ML 0.3–1.3 mm, covering the M2/FrA region). The cranial window
was filled with silicon gel, covered with a glass coverslip, and sealed with
dental cement. A head plate was glued on the skull for fixation during imaging.
The animals were then taken off the anesthesia and allowed to recover
for 1 hr before imaging.
VTA Stimulation and GCaMP6 Imaging
VTA was stimulated with electrical pulses (0.7 mA, 0.2 ms per pulse, and one,
five, or ten pulses at 50 Hz per stimulus train). A two-photon microscope
(FV1000, Olympus) was used to image the brain under the cranial window
(excitation laser: 900 nm) using a 203 water-immersion lens (numerical aper-
ture [NA] 0.95). Time series images lasting40 s (115 frames at 0.351 s/frame)
were taken for each stimulus train, with the VTA stimulus delivered at 20 s after
the start of imaging. For saline, SKF38393 (10 mg/kg, i.p.) and SCH23390
(1 mg/kg, i.p.) injection experiments, GCaMP6 response to the ten-pulse
(50 Hz) VTA stimulation was imaged before and 30 min after the injection.Cell Reports 16, 2116–2128, August 23, 2016 2125
Image Analysis
Images were analyzed using NIH ImageJ. The mean pixel intensity in each
image frame of the time series was calculated as Ft. Baseline fluorescence
(F0) was defined as the average of the fluorescent signals (Ft) in the first
15 s of the time series. Changes in calcium signals (DF/F) are calculated as
(Ft  F0)/F0.
Slice Surface Biotinylation, Antibodies, and Western Blot Analyses
Details are reported in the Supplemental Experimental Procedures.
Statistical Analysis
Results are expressed as mean ± SEM throughout. One- or two-way ANOVAs
were applied to compare the group means. Newman-Keul’s post hoc test was
used for making comparisons between groups when the overall ANOVA
showed statistical significant differences for the main factors. The accepted
value for significance was p% 0.05. Statistical analyses were performed using
Statistica 11 (StatSoft).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supplemental
Experimental Procedures, seven figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.celrep.2016.07.044.
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